Protein‑ and growth‑modulatory effects of carcinoma‑associated fibroblasts on breast cancer cells: Role of interleukin‑6

Dittmer,Angela; Lange,Theresia; Leyh,Benjamin; Dittmer,Jürgen

doi:10.3892/ijo.2019.4918

Protein‑ and growth‑modulatory effects of carcinoma‑associated fibroblasts on breast cancer cells: Role of interleukin‑6

Authors:
- Angela Dittmer
- Theresia Lange
- Benjamin Leyh
- Jürgen Dittmer
View Affiliations

Affiliations: Clinic for Gynecology, Martin Luther University Halle‑Wittenberg, 06120 Halle/Saale, Germany
Published online on: November 22, 2019 https://doi.org/10.3892/ijo.2019.4918
Pages: 258-272
Copyright: © Dittmer et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carcinoma‑associated fibroblasts (CAFs) secrete factors that increase the expression and/or activities of proteins in breast cancer cells and induce resistance to anti‑estrogens, such as fulvestrant. A major factor is interleukin‑6 (IL‑6). This study demonstrated that, across estrogen receptor (ER)α‑positive and ‑negative cell lines, recombinant human IL‑6 (rhIL‑6) mimicked most of the CAF‑conditioned medium (CM)‑induced changes in protein expression patterns; however, in most cases, it failed to recapitulate CAF‑CM‑triggered alterations in ERK1/2 and AKT activities. The ability of rhIL‑6 to induce fulvestrant resistance was dependent upon the culture conditions. In 3D, but not in 2D cultures, rhIL‑6 increased the survival of fulvestrant‑treated cells, although not to the same extent as observed with CAF‑CM. In 2D cultures, rhIL‑6 acted in a pro‑apoptotic manner and decreased the expression of ATP‑binding cassette transporter G2 (ABCG2). The inhibition of the PI3K/AKT pathway had similar effects on apoptosis and ABCG2 expression, linking the failure of rhIL‑6 to induce fulvestrant resistance to its inability to activate the PI3K/AKT pathway. In 3D cultures, both CAF‑CM and rhIL‑6 acted in an anti‑apoptotic manner. These activities are likely independent on the PI3K/AKT pathway and ABCG2. Experiments on ERα‑negative breast cancer cells revealed a growth‑inhibitory effects of both CAF‑CM and rhIL‑6, which coincided with a reduction in the c‑Myc level. These data suggest that IL‑6 plays a role in several effects of CAF‑CM, including alterations in protein expression patterns, fulvestrant resistance in 3D cultures and growth inhibition. By contrast, IL‑6 is unlikely to be responsible for the CAF‑CM‑induced activation of the PI3K/AKT pathway and fulvestrant resistance in 2D cultures.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
3	Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011. View Article : Google Scholar
4	Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 357:39–51. 2007. View Article : Google Scholar : PubMed/NCBI
5	Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S and Piacentini F: Neoadjuvant treatments in triple-negative breast cancer patients: Where we are now and where we are going. Cancer Manag Res. 10:91–103. 2018. View Article : Google Scholar : PubMed/NCBI
6	Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, Rees M, Ramaswamy A, Muenst S, Soysal SD, et al: A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 177:1330–1345.e18. 2019. View Article : Google Scholar : PubMed/NCBI
7	Hong D, Fritz AJ, Zaidi SK, van Wijnen AJ, Nickerson JA, Imbalzano AN, Lian JB, Stein JL and Stein GS: Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. J Cell Physiol. 233:9136–9144. 2018. View Article : Google Scholar : PubMed/NCBI
8	Dittmer J: Breast cancer stem cells: Features, key drivers and treatment options. Semin. Cancer Biol. 53:59–74. 2018. View Article : Google Scholar
9	Bailey TA, Luan H, Clubb RJ, Naramura M, Band V, Raja SM and Band H: Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog. 10:282011. View Article : Google Scholar : PubMed/NCBI
10	Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 9:631–643. 2009. View Article : Google Scholar : PubMed/NCBI
11	Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 62:233–247. 2011. View Article : Google Scholar
12	Dittmer J and Leyh B: The impact of tumor stroma on drug response in breast cancer. Semin Cancer Biol. 31:3–15. 2015. View Article : Google Scholar
13	Leyh B, Dittmer A, Lange T, Martens JW and Dittmer J: Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis. Oncotarget. 6:39307–39328. 2015. View Article : Google Scholar : PubMed/NCBI
14	Pratt MA, Bishop TE, White D, Yasvinski G, Ménard M, Niu MY and Clarke R: Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: Roles in growth and hormone independence. Mol Cell Biol. 23:6887–6900. 2003. View Article : Google Scholar : PubMed/NCBI
15	Chen X, Cao X, Sun X, Lei R, Chen P, Zhao Y, Jiang Y, Yin J, Chen R, Ye D, et al: Bcl-3 regulates TGFβ signaling by stabi-lizing Smad3 during breast cancer pulmonary metastasis. Cell Death Dis. 7:e25082016. View Article : Google Scholar
16	Schuster M, Annemann M, Plaza-Sirvent C and Schmitz I: Atypical IκB proteins - nuclear modulators of NF-κB signaling. Cell Commun Signal. 11:232013. View Article : Google Scholar
17	Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY and Van Laere SJ: The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res. 14:2122012. View Article : Google Scholar
18	Wang VY, Li Y, Kim D, Zhong X, Du Q, Ghassemian M and Ghosh G: Bcl3 Phosphorylation by Akt, Erk2, and IKK is required for its transcriptional activity. Mol Cell. 67:484–497.e5. 2017. View Article : Google Scholar : PubMed/NCBI
19	Baxter RC: IGF binding proteins in cancer: Mechanistic and clinical insights. Nat Rev Cancer. 14:329–341. 2014. View Article : Google Scholar : PubMed/NCBI
20	Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, Hayashi S, Fujii Y, Iwase H and Yamashita H: Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol. 37:575–582. 2007. View Article : Google Scholar : PubMed/NCBI
21	Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM and Haluska P: IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res. 18:1808–1817. 2012. View Article : Google Scholar : PubMed/NCBI
22	West NR: Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines. Front Immunol. 10:10932019. View Article : Google Scholar : PubMed/NCBI
23	Boulanger MJ, Chow DC, Brevnova EE and Garcia KC: Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 300:2101–2104. 2003. View Article : Google Scholar : PubMed/NCBI
24	Schaper F and Rose-John S: Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 26:475–487. 2015. View Article : Google Scholar : PubMed/NCBI
25	Avalle L, Pensa S, Regis G, Novelli F and Poli V: STAT1 and STAT3 in tumorigenesis: A matter of balance. JAK-STAT. 1:65–72. 2012. View Article : Google Scholar : PubMed/NCBI
26	Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
27	Lacina L, Brábek J, Král V, Kodet O and Smetana K Jr: Interleukin-6: A molecule with complex biological impact in cancer. Histol Histopathol. 34:125–136. 2019.
28	Hodge DR, Hurt EM and Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
29	Morrow RJ, Etemadi N, Yeo B and Ernst M: Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer. Mediators Inflamm. 2017:47548272017. View Article : Google Scholar : PubMed/NCBI
30	Ghandadi M and Sahebkar A: Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance. Curr Pharm Des. 22:518–526. 2016. View Article : Google Scholar
31	Kim SY, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT and Lee YJ: Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal. 25:961–969. 2013. View Article : Google Scholar : PubMed/NCBI
32	Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM and Hall BM: Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 28:2940–2947. 2009. View Article : Google Scholar : PubMed/NCBI
33	Yadav A, Kumar B, Datta J, Teknos TN and Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
34	Brooks MD, Burness ML and Wicha MS: Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell. 17:260–271. 2015. View Article : Google Scholar : PubMed/NCBI
35	Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, et al: Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 47:570–584. 2012. View Article : Google Scholar : PubMed/NCBI
36	Saha S, Mukherjee S, Khan P, Kajal K, Mazumdar M, Manna A, Mukherjee S, De S, Jana D, Sarkar DK, et al: Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. Cancer Res. 76:2000–2012. 2016. View Article : Google Scholar : PubMed/NCBI
37	Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, et al: Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71:614–624. 2011. View Article : Google Scholar : PubMed/NCBI
38	Dittmer J: Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol. 44:72–82. 2017. View Article : Google Scholar : PubMed/NCBI
39	Zhang GJ and Adachi I: Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19(2B): 1427–1432. 1999.PubMed/NCBI
40	Casneuf T, Axel AE, King P, Alvarez JD, Werbeck JL, Verhulst T, Verstraeten K, Hall BM and Sasser AK: Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-a-positive breast cancer. Breast Cancer (Dove Med Press). 8:13–27. 2016.
41	Zhang W, Guo J, Li S, Ma T, Xu D, Han C, Liu F, Yu W and Kong L: Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy. Sci Rep. 7:463522017. View Article : Google Scholar : PubMed/NCBI
42	Dittmer A and Dittmer J: Long-term exposure to carcinoma-associated fibroblasts makes breast cancer cells addictive to integrin β1. Oncotarget. 9:22079–22094. 2018. View Article : Google Scholar : PubMed/NCBI
43	Dittmer A and Dittmer J: Beta-actin is not a reliable loading control in Western blot analysis. Electrophoresis. 27:2844–2845. 2006. View Article : Google Scholar : PubMed/NCBI
44	Moritz CP: Tubulin or Not Tubulin: Heading Toward Total Protein Staining as Loading Control in Western Blots. Proteomics. 17:172017. View Article : Google Scholar
45	Dittmer A, Schunke D and Dittmer J: PTHrP promotes homotypic aggregation of breast cancer cells in three-dimensional cultures. Cancer Lett. 260:56–61. 2008. View Article : Google Scholar
46	Oerlecke I, Bauer E, Dittmer A, Leyh B and Dittmer J: Cyclic AMP enhances TGFβ responses of breast cancer cells by upregulating TGFβ receptor I expression. PLoS One. 8:e542612013. View Article : Google Scholar
47	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
48	Kalluri R: The biology and function of fibroblasts in cancer. Nat Rev Cancer. 16:582–598. 2016. View Article : Google Scholar : PubMed/NCBI
49	Brocke-Heidrich K, Ge B, Cvijic H, Pfeifer G, Löffler D, Henze C, McKeithan TW and Horn F: BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene. 25:7297–7304. 2006. View Article : Google Scholar : PubMed/NCBI
50	Liu Z, Jiang Y, Hou Y, Hu Y, Cao X, Tao Y, Xu C, Liu S, Wang S, Wang L, et al: The IκB family member Bcl-3 stabilizes c-Myc in colorectal cancer. J Mol Cell Biol. 5:280–282. 2013. View Article : Google Scholar : PubMed/NCBI
51	Bretones G, Delgado MD and León J: Myc and cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015. View Article : Google Scholar
52	Massoumi R, Chmielarska K, Hennecke K, Pfeifer A and Fässler R: Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell. 125:665–677. 2006. View Article : Google Scholar : PubMed/NCBI
53	Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, Joffé EB and Simian M: The tumor microenvironment modulates tamoxifen resistance in breast cancer: A role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Res Treat. 133:459–471. 2012. View Article : Google Scholar
54	Sánchez-Pérez Y, Chirino YI, Osornio-Vargas AR, Herrera LA, Morales-Bárcenas R, López-Saavedra A, González-Ramírez I, Miranda J and García-Cuellar CM: Cytoplasmic p21(CIP1/WAF1), ERK1/2 activation, and cytoskeletal remodeling are associated with the senescence-like phenotype after airborne particulate matter (PM(10)) exposure in lung cells. Toxicol Lett. 225:12–19. 2014. View Article : Google Scholar
55	Yousefi B, Rahmati M and Ahmadi Y: The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life Sci. 99:14–17. 2014. View Article : Google Scholar : PubMed/NCBI
56	Chiu JJ, Sgagias MK and Cowan KH: Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res. 2:215–221. 1996.PubMed/NCBI
57	Kathawala RJ, Gupta P, Ashby CRJ Jr and Chen ZS: The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
58	Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
59	DuFort CC, Paszek MJ and Weaver VM: Balancing forces: Architectural control of mechanotransduction. Nat Rev Mol Cell Biol. 12:308–319. 2011. View Article : Google Scholar : PubMed/NCBI
60	Dittmer A, Fuchs A, Oerlecke I, Leyh B, Kaiser S, Martens JW, Lützkendorf J, Müller L and Dittmer J: Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. Int J Oncol. 39:689–696. 2011.PubMed/NCBI
61	Dittmer A, Hohlfeld K, Lützkendorf J, Müller LP and Dittmer J: Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cell Mol Life Sci. 66:3053–3065. 2009. View Article : Google Scholar : PubMed/NCBI
62	Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE and Hall BM: Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J. 21:3763–3770. 2007. View Article : Google Scholar : PubMed/NCBI
63	Bharti R, Dey G, Ojha PK, Rajput S, Jaganathan SK, Sen R and Mandal M: Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene. 35:3965–3975. 2016. View Article : Google Scholar
64	Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H and Efstratiadis A: Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA. 106:2359–2364. 2009. View Article : Google Scholar : PubMed/NCBI
65	Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum JY, Lambin P, Dubois L, Pavathaneni NK, et al: Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget. 6:24856–24870. 2015. View Article : Google Scholar : PubMed/NCBI
66	Chen CR, Kang Y and Massagué J: Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA. 98:992–999. 2001. View Article : Google Scholar : PubMed/NCBI
67	Friedrich K, Dolznig H, Han X and Moriggl R: Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3. Biosci Trends. 11:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
68	Marconett CN, Singhal AK, Sundar SN and Firestone GL: Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells. Mol Cell Endocrinol. 363:74–84. 2012. View Article : Google Scholar : PubMed/NCBI
69	Gaben AM, Sabbah M, Redeuilh G, Bedin M and Mester J: Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer. 12:2912012. View Article : Google Scholar : PubMed/NCBI
70	Sun J, Lu Z, Deng Y, Wang W, He Q, Yan W and Wang A: Up-regulation of INSR/IGF1R by C-myc promotes TSCC tumorigenesis and metastasis through the NF-κB pathway. Biochim Biophys Acta Mol Basis Dis. 1864(5 Pt A): 1873–1882. 2018. View Article : Google Scholar : PubMed/NCBI
71	Ansari MF, Idrees D, Hassan MI, Ahmad K, Avecilla F and Azam A: Design, synthesis and biological evaluation of novel pyridine-thiazolidinone derivatives as anticancer agents: Targeting human carbonic anhydrase IX. Eur J Med Chem. 144:544–556. 2018. View Article : Google Scholar : PubMed/NCBI
72	Sedlakova O, Svastova E, Takacova M, Kopacek J, Pastorek J and Pastorekova S: Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front Physiol. 4:4002014. View Article : Google Scholar : PubMed/NCBI
73	Jung YJ, Isaacs JS, Lee S, Trepel J and Neckers L: IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17:2115–2117. 2003. View Article : Google Scholar : PubMed/NCBI
74	Wang K, Zhu X, Zhang K, Yin Y, Chen Y and Zhang T: Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1a. J Biochem Mol Toxicol. 32:e220392018. View Article : Google Scholar
75	Nass N, Dittmer A, Hellwig V, Lange T, Beyer JM, Leyh B, Ignatov A, Weiβenborn C, Kirkegaard T, Lykkesfeldt AE, et al: Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response. Oncotarget. 7:38408–38426. 2016. View Article : Google Scholar : PubMed/NCBI
76	Hamurcu Z, Kahraman N, Ashour A and Ozpolat B: FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer. Breast Cancer Res Treat. 163:485–493. 2017. View Article : Google Scholar : PubMed/NCBI
77	Gache C, Berthois Y, Martin PM and Saez S: Positive regulation of normal and tumoral mammary epithelial cell proliferation by fibroblasts in coculture. In. Vitro Cell Dev Biol Anim. 34:347–351. 1998. View Article : Google Scholar
78	Chen L, Shulman LM and Revel M: IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells. J Biol Regul Homeost Agents. 5:125–136. 1991.PubMed/NCBI
79	Badache A and Hynes NE: Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res. 61:383–391. 2001.PubMed/NCBI
80	Ikeda O, Sekine Y, Mizushima A, Nakasuji M, Miyasaka Y, Yamamoto C, Muromoto R, Nanbo A, Oritani K, Yoshimura A, Matsuda T, et al: Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. J Biol Chem. 285:38093–38103. 2010. View Article : Google Scholar : PubMed/NCBI
81	Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, Molinolo AA, Frahm I, Charreau EH, Schillaci R, et al: Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol. 25:4826–4840. 2005. View Article : Google Scholar : PubMed/NCBI
82	Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK and Maheswaran S: Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J Biol Chem. 275:28371–28379. 2000. View Article : Google Scholar : PubMed/NCBI
83	Ping B, He X, Xia W, Lee DF, Wei Y, Yu D, Mills G, Shi D and Hung MC: Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKβ overexpression in human breast cancers. Int J Oncol. 29:1103–1110. 2006.PubMed/NCBI
84	Neve RM, Sutterlüty H, Pullen N, Lane HA, Daly JM, Krek W and Hynes NE: Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 19:1647–1656. 2000. View Article : Google Scholar : PubMed/NCBI
85	Weigelt B, Lo AT, Park CC, Gray JW and Bissell MJ: HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D micro-environment. Breast Cancer Res Treat. 122:35–43. 2010. View Article : Google Scholar
86	Hugo HJ, Lebret S, Tomaskovic-Crook E, Ahmed N, Blick T, Newgreen DF, Thompson EW and Ackland ML: Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment. Cancer Microenviron. 5:83–93. 2012. View Article : Google Scholar : PubMed/NCBI
87	Mao Y, Zhang Y, Qu Q, Zhao M, Lou Y, Liu J, Huang O, Chen X, Wu J and Shen K: Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells. Mol Biosyst. 11:1029–1040. 2015. View Article : Google Scholar : PubMed/NCBI
88	Gallo M, Frezzetti D, Roma C, Chicchinelli N, Barbieri A, Arra C, Scognamiglio G, Botti G, De Luca A and Normanno N: RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells. Oncotarget. 9:17543–17553. 2018. View Article : Google Scholar : PubMed/NCBI
89	Singh S, Murillo G, Chen D, Parihar AS and Mehta RG: Suppression of Breast Cancer Cell Proliferation by Selective Single-Domain Antibody for Intracellular STAT3. Breast Cancer (Auckl). 12:11782234177508582018.
90	Mosteiro L, Pantoja C, de Martino A and Serrano M: Senescence promotes in vivo reprogramming through p16INK4a and IL-6. Aging Cell. 17:172018. View Article : Google Scholar
91	Correia AL and Bissell MJ: The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 15:39–49. 2012. View Article : Google Scholar : PubMed/NCBI